SAN FRANCISCO– ValGenesis, Inc. (“ValGenesis”), the market leader in Enterprise Validation Lifecycle Management Systems (VLMS), announced the closing of a $24 million investment from Morgan Stanley Expansion Capital. Proceeds will bolster sales and accelerate ValGenesis’ focus on innovation in digital validation technologies and global deployment.
ValGenesis is the inventor and first-mover to digitize the validation lifecycle process. ValGenesis VLMS is the industry’s first, proven, 100% end-to-end paperless validation lifecycle management solution, trusted by global life science organizations as a system of record for validation. Covering the entire validation lifecycle process, ValGenesis VLMS delivers technology solutions that are validated, fully configurable, and rapidly deployable through a private secured Cloud.
“The world of digitalization has emerged so strongly that today it is an inescapable part of life broadly and specifically in the life science industry. Technologies such as artificial intelligence (AI), the internet of things (IoT), and augmented reality (AR) are essential for supporting remote process management, including validation in the life science industry. ValGenesis is at the cutting edge of digital validation technology and is trusted by over 30 of the top 50 global life science companies. We are thrilled to secure this funding from Morgan Stanley Expansion Capital; it will help us aggressively pursue our vision of becoming the de facto standard for digital validation lifecycle management,” says Dr. Siva Samy, CEO & Chief Product Strategist of ValGenesis, Inc.
“Digitization of backend processes and workflow automation is a rapidly emerging area of growth for healthcare and life sciences companies. As a market leader, ValGenesis offers a fit-for-purpose platform for validation lifecycle management, resulting in significant cost and time efficiencies for global, compliance focused organizations,” said Melissa Daniels, Managing Director, Morgan Stanley Expansion Capital. “We believe ValGenesis’ VLMS offers a compelling value proposition, and are excited to partner with Dr. Samy, a visionary in the VLMS market, to support the company as it continues on its growth trajectory.”
The funding builds on a successful 2020 during which ValGenesis augmented its VLMS to leverage new, cutting-edge digital validation technologies, helping ValGenesis build up a large customer base across the globe. With the latest round of investment, ValGenesis will continue to focus on driving innovative validation technology solutions that solve today’s most significant challenges in the life science industry.
